Jul 28, 2021 8:00am EDT Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
Jun 25, 2021 7:00am EDT Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
Jun 24, 2021 8:00am EDT Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
May 25, 2021 8:00am EDT Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
May 20, 2021 8:00am EDT Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
May 17, 2021 7:00am EDT Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021 8:00am EDT Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
Apr 26, 2021 8:00am EDT Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Apr 10, 2021 2:15pm EDT Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
